Bellevue Group AG
SEC Form 13F institutional filer · CIK 0001674546
13F-HR · 65 reported holdings · 2026-03-31
Swiss financial services group.
Reported long-US-equity value
$1.99B
Top-10 concentration
67.8%
Bellevue Group AG — $1.99B AUM allocation strategy
Bellevue Group AG files SEC Form 13F and reports $1.99B of long US equity value across 65 reported holdings for 2026-03-31.
Its largest sector bet is Health Care 86.3%.
The top 10 holdings account for 68% of reported value — a conviction-weighted book concentrated in its best ideas. The sector and industry splits below are of the same reported value. Track quarter-over-quarter adds, trims, new positions and exits below — sourced from SEC 13F filings, public domain.
Bellevue Group AG — latest SEC 13F insights
Reported long-US-equity value (13F AUM)
$1.99B
total across 65 reported holdings · 2026-03-31 · excludes shorts, cash, non-US
Top-10 concentration
68% of value
higher = narrower conviction; lower = spread / hedging
Biggest adds (shares)
+$GILD +1.12M sh · +$157M+$AMGN +277K sh · +$97.9M+$REGN +265K sh · +$205M
Biggest trims (shares)
−$EW −204K sh · −$21.7M−$ABT −165K sh · −$46.8M−$BDX −144K sh · −$32.4M
Exited to nil (held last quarter, gone now)
$KKR ($3.45M last qtr)$ANET ($629K last qtr)$IWM ($566K last qtr)$META ($528K last qtr)$LULU ($465K last qtr)
Sector allocation (share of reported value)
- $XLVHealth Care86.3%—
- Other holdings13.7%—
each slice is a share of the reported long-US-equity value — smaller sectors and the rest of the book roll into “Other holdings”
Qtr shift = share-point change vs the prior quarter's filing — first period tracked for this filer; the column fills in with the next quarterly refresh.
Industry allocation (share of reported value)
- Biotechnology39.5%—
- Health Care Equipment38.3%—
- Life Sciences Tools & Services3.5%—
- Pharmaceuticals3.0%—
- Managed Health Care2.0%—
- Other holdings13.7%—
the finer GICS cut of the same book — same denominator — smaller industries roll into “Other holdings”
Qtr shift = share-point change vs the prior quarter's filing — first period tracked for this filer; the column fills in with the next quarterly refresh.
Top S&P 500 holdings
10 of 10 rows · sorted by Value ↓
| Ticker | Holding | Shares | Value | Δ QoQ | Weight |
|---|---|---|---|---|---|
| $VRTX | Vertex Pharmaceuticals Incorporated | 682K | $304M | +788 | 15.3% |
| $REGN | Regeneron Pharmaceuticals Inc | 279K | $215M | +265K | 10.8% |
| $GILD | Gilead Sciences Inc | 1.17M | $163M | +1.12M | 8.2% |
| $ISRG | Intuitive Surgical Inc | 287K | $132M | -35.4K | 6.6% |
| $ABT | Abbott Laboratories | 1.15M | $118M | -165K | 5.9% |
| $AMGN | Amgen Inc | 295K | $104M | +277K | 5.2% |
| $BSX | Boston Scientific Corporation | 1.47M | $92M | -92.7K | 4.6% |
| $MDT | Medtronic plc | 957K | $83M | +191K | 4.2% |
| $SYK | Stryker Corporation | 217K | $71.4M | -143K | 3.6% |
| $EW | Edwards Lifesciences Corporation | 839K | $67.2M | -204K | 3.4% |
…and 55 more holdings in the full 13F filing (top positions only shown).
SEC Form 13F data sets · public domain · 45-day filing lag · >$100M AUM managers · as reported
← All 13F filers·← QuantOrb.pro
How to read Δ QoQ — the five insight categories, and the caveats
The categories. Analysts, quants and retail traders look past total portfolio value to isolate actionable signals. Five categories matter.
Conviction & concentration shifts
New positions vs complete exits — a brand-new stock signals high conviction; a full liquidation suggests a broken thesis or tax-loss harvesting. Aggressive sizing — look at share count, not dollars: a 20% share increase during a drawdown is strong dip-buying. Concentration — a narrowing top-5/10 means conviction; spreading capital across more names means hedging.
Sector & macro allocation rotations
Aggregating Δ QoQ moves across sectors shows where smart money is leaning in or sneaking out — rotating out of growth into defensives or energy, for example. The fund's total long equity exposure quarter-over-quarter is a proxy for overall institutional risk appetite.
Crowding & smart-money consensus
When several managers initiate or expand the same stock in the same quarter, that is institutional consensus. Contrarian reads: top pickers buying hard into a beaten-down name the market is selling.
Derivative & option overlays
Reported call/put changes indicate whether managers are adding downside hedges or leveraging upside exposure. Note: a long increase may be half of a market-neutral pair trade.
Who reads this
| Retail "cloners" | High-conviction ideas to replicate ~45 days after quarter-end. |
| Corporate IR | Which funds bought or dumped the stock, before the next call. |
| Quant / algo traders | Cross-sectional factor inputs: flow, momentum, ownership. |
Four caveats before you trade on it
- 45-day lag — holdings are quarter-end; positions may already be closed.
- Long-only — 13Fs miss shorts, pair trades and cash.
- No non-US / fixed income — the picture is US equities plus options.
- Corporate actions — splits and spinoffs distort raw share deltas.
Newsletter signup
Free subscription. Daily trading day morning dispatch. No spam.